Evidence map›Paper›PMID 33598560›Full record

ArticleEuropean stroke journal2020

STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial.

Kristin Tveitan Larsen, Elisabeth Forfang, Johanna Pennlert, Eva-Lotta Glader, Christina Kruuse, Per Wester, Hege Ihle-Hansen, Maria Carlsson, Eivind Berge, Rustam Al-Shahi Salman and 2 more

Open access · hybridAbstract read
In one paragraph

Article in European stroke journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Kristin Tveitan LarsenDepartment of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-1310-8243
Elisabeth ForfangUniversity of Oslo, Institute of Clinical Medicine, Oslo, Norway.
Johanna PennlertDepartment of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden.
Eva-Lotta GladerDepartment of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden.
Christina KruuseHerlev Gentofte Hospital and University of Copenhagen, Herlev, Denmark.
Per WesterDepartment of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden.
Hege Ihle-HansenUniversity of Oslo, Institute of Clinical Medicine, Oslo, Norway.
Maria CarlssonDepartment of Neurology, Nordland Hospital Trust, Bodø, Norway.
Eivind BergeDepartment of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
Rustam Al-Shahi SalmanCentre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Torgeir Bruun WyllerDepartment of Geriatric Medicine, Oslo University Hospital, Oslo, Norway.
Ole Morten RønningUniversity of Oslo, Institute of Clinical Medicine, Oslo, Norway.ORCID https://orcid.org/0000-0001-5080-5788
Oslo University Hospital · NOUmeå University · SEUniversity of Oslo · NODanderyds sjukhus · SEMRC Centre for Regenerative Medicine · GBNordland Hospital Trust · NOUniversity of Copenhagen · DK

Funding

British Heart Foundation CS/18/2/33719British Heart Foundation FS/13/72/30531British Heart Foundation PG/14/50/30891British Heart Foundation SP/12/2/29422Medical Research Council G1002605
6 · The paper itself

Abstract

BACKGROUND AND

aimsMany patients with prior intracerebral haemorrhage have indications for antithrombotic treatment with antiplatelet or anticoagulant drugs for prevention of ischaemic events, but it is uncertain whether such treatment is beneficial after intracerebral haemorrhage. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage will assess (i) the effects of long-term antithrombotic treatment on the risk of recurrent intracerebral haemorrhage and occlusive vascular events after intracerebral haemorrhage and (ii) whether imaging findings, like cerebral microbleeds, modify these effects.

methodsSTudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is a multicentre, randomised controlled, open trial of starting versus avoiding antithrombotic treatment after non-traumatic intracerebral haemorrhage, in patients with an indication for antithrombotic treatment. Participants with vascular disease as an indication for antiplatelet treatment are randomly allocated to antiplatelet treatment or no antithrombotic treatment. Participants with atrial fibrillation as an indication for anticoagulant treatment are randomly allocated to anticoagulant treatment or no anticoagulant treatment. Cerebral CT or MRI is performed before randomisation. Duration of follow-up is at least two years. The primary outcome is recurrent intracerebral haemorrhage. Secondary outcomes include occlusive vascular events and death. Assessment of clinical outcomes is performed blinded to treatment allocation. Target recruitment is 500 participants.

Indexed as

anticoagulantantiplateletantithrombotic treatmentatrial fibrillationIntracerebral haemorrhageischaemic eventsrandomised controlled trialsecondary preventionstroke

Identifiers

PMID33598560
PMCPMC7856578
OpenAlexW3083381649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.